A New CDx for NSCLC is here. The VENTANA PD-L1 (SP263) Assay is now FDA approved.
The VENTANA PD-L1 (SP263) Assay is an FDA-approved CDx that enables your lab to identify NSCLC patients eligible for treatment with TECENTRIQ (atezolizumab) in early stage NSCLC
Ordering information
VENTANA PD-L1 (SP263) Assay
Material Number: 07208162001
Part Number: 740-4907
Additional Education
VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody Class I
PD-L1 is an informative immunotherapy biomarker: Aberrant expression of PD-L1 on tumor and immune cells
in the tumor microenvironment impedes anti-tumor immunity, allowing tumors to grow and metastasize.
Broad Tissue Application
Aids in PD-L1 Expression for Many Tumor Types
The VENTANA PD-L1 (SP263) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the PD-L1 protein in the formalin-fixed, paraffin-embedded tissue. It is intended to be used on the BenchMark Ultra. It is indicated as an aid in the assessment of PD-L1 expression in human tissues.
*In the US only available on the BenchMark ULTRA Instrument
Ordering information
VENTANA PD-L1 (SP263) Rabbit Monoclonal Antibody
Material Number: 07494190001
Part Number: 790-4905
About PD-L1
PD-L1 is a transmembrane protein that down-regulates immune responses through binding to its two inhibitory receptors, programmed death-1 (PD-1) and B7.1. PD-1 is an inhibitory receptor expressed on T cells following T-cell activation, which is sustained in states of chronic stimulation such as in chronic infection or cancer.1 Binding of PD-L1 with PD-1 inhibits T cell proliferation, cytokine production and cytolytic activity, leading to the functional inactivation or exhaustion of T cells. B7.1 is a molecule expressed on antigen presenting cells and activated T cells. PD-L1 binding to B7.1 on T cells and antigen presenting cells can mediate down-regulation of immune responses, including inhibition of T-cell activation and cytokine production.2 PD-L1 expression has been observed in immune cells and tumor cells.3,4 Aberrant expression of PD-L1 on tumor cells has been reported to impede anti-tumor immunity, resulting in immune evasion.1 Therefore, interruption of the PD-L1/PD-1 pathway represents an attractive strategy to reinvigorate tumor-specific T cell immunity suppressed by the expression of PD-L1 in the tumor microenvironment.
Plays a key role in tumor progression
What is the tumor microenvironment (TME)?
The tumor microenvironment (TME) consists of different cellular, including immune cells, and non-cellular components in and around the tumor. The TME has been recognized to play a significant role in tumor progression.1,2
Why is the TME important?
The TME shapes tumor evolution (whether the tumor regresses, develops resistance, evades the immune system and/or metastasizes) and consequently impacts patient outcomes.3 An association has been observed between the levels of tumor infiltrating immune cells, key components of the TME, and patient prognosis: a colorectal cancer study showed that higher levels of tumor infiltrating CD3+ immune cells were associated with better disease free survival.4
What is the role of PD-L1 in the TME?
Aberrant expression of PD-L1 on tumor cells has been reported to impede anti-tumor immunity, resulting in immune evasion.5 Therefore, interruption of the PD-L1/PD-1 pathway represents an attractive strategy to reinvigorate tumor-specific T cell immunity suppressed by the expression of PD-L1 in the TME. This approach has proven effective.
Research Use Only
Learn More about the RUO PD-L1 (SP263) Image Analysis Algorithm
RUO: SP263 Image Analysis Algorithm Video
Intro to uPath PD-L1 SP263 Image Analysis Algorithm
NEW: Roche uPath Image Analysis Algorithms
PD-L1 (SP263) Image Analysis NSCLC Brochure